Suman Chowdhury*

Department of Pharmacology, Physiology, Neuroscience, Rutgers University, USA

*Corresponding Author: Suman Chowdhury, Department of Pharmacology, Physiology, Neuroscience, Rutgers University, USA.

Received: February 09, 2022 Published: March 30, 2022

Preface

Alzheimer’s disease (AD) is an irreversible, progressive and most common cause of dementia that destroys memory and thinking skill, it remains a global health concern with ever aging population. Discovered by Alois Alzheimer’s in 1906 [1], AD have been identified in 43.8 million people worlds wide [2]. The pathological hallmarks of AD are intraneuronal neurofibrillary tangles (NFTs), extracellular deposits of amyloid-β (Aβ) peptides as ‘‘senile’’ β-amyloid plaques and decrease in neuronal cells.

References

1. Hippius Hanns and Gabriele Neundörfer. "The discovery of Alzheimer's disease”. Dialogues in Clinical Neuroscience1 (2003): 101.
2. Nichols Emma., et al. "Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016”. The Lancet Neurology1 (2019): 88-106.
3. Cummings Jeffrey L., et al. "The costs of developing treatments for Alzheimer's disease: A retrospective exploration”. Alzheimer's and Dementia(2021).
4. Alzheimer's Association. "Changing the trajectory of Alzheimer's disease”. Facts and Figures(2010).
5. US Food and Drug Administration. "FDA grants accelerated approval for Alzheimer’s drug” (2021): 2021.
6. Sevigny Jeff., et al. "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease”. Nature7618 (2016): 50-56.
7. Weitz Tara M and Terrence Town. "Amyloid cascade into clarity”. Immunity4 (2016): 717-718.
8. Siemers Eric R., et al. "Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients”. Alzheimer's and Dementia2 (2016): 110-120.
9. Salloway Stephen., et al. "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease”. New England Journal of Medicine4 (2014): 322-333.
10. Honig Lawrence S., et al. "Trial of solanezumab for mild dementia due to Alzheimer’s disease”. New England Journal of Medicine4 (2018): 321-330.
11. Cummings Jeffrey L., et al. "ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease”. Neurology21 (2018): e1889-e1897.
12. Mahase Elisabeth. "Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns”. BMJ 375 (2021): n3127.

Citation

Citation: Suman Chowdhury. “Aducanumab, an FDA Approved Drug for Alzheimer’s Disease". Acta Scientific Pharmacology 3.4 (2022): 26-28.

Copyright

Copyright: © 2022 Suman Chowdhury. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.